跳至主要内容
临床试验/NCT01850342
NCT01850342Unknown1 期

Effectiveness and Safety of Cell-Assisted Lipotransfer for the Treatment of Stress Urinary Incontinence Via Endoscopically-Assisted Administration of Fat Tissue Micrografts Enriched by Autologous Adipose-Derived Regenerative Cells

Burnasyan Federal Medical Biophysical Center2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2013年5月1日最近更新:
适应症

试验速览

阶段
1 期
发起方
入组人数
12
试验地点
2
主要终点
Safety endpoints

研究概览

简要总结

Autologous washed and homogenized fat micrograft harvested from the patient's front abdominal wall enriched with adipose-derived regenerative cells (ADRC) derived by enzyme-treatment of a portion of the harvested fat. Fat tissue micrograft mixed with ADRC will be administered one-time endoscopically into submucosal layer of urethra under eye control. This is a single arm study with no control. All patients receive cell therapy.

详细描述

Fat tissue obtainment. Subjects will undergo liposuction under local anesthesia. In this procedure, Ringer's solution with the anesthetic lidocaine and vasoconstrictor adrenaline infused into the adipose compartment to minimize blood loss and contamination of the tissue by peripheral blood cells. 15 minutes later a hollow blunt-tipped 3 mm cannula introduced into the subcutaneous space through small (0.5 cm) incision. The cannula attached to syringe and under gentle suction moved through the adipose compartment, mechanically disrupting the fat tissue. Aspirate volume - approximately 150 cc. Procedure time - 30 minutes.

ADRC isolation. Aspirated fat tissue placed into sterile tubes with transport medium and delivered into the laboratory within 15 minutes. To isolate the ADRC, part of lipoaspirate (approximately 100 cc) washed extensively with equal volumes of phosphate-buffered saline and digested with collagenase. After enzyme activity neutralization decomposed fat tissue eliminated and ADRC washed 3 times with saline. Cells divided into 3 portions. First portion used for counting, viability and sterility assessment. Second portion prepared for freezing in liquid nitrogen. Third portion mixed with fat micrograft.

Fat tissue enriched micrograft preparation. Obtained fat tissue (approximately 20-30 cc) washed repeatedly. Aspirated fat settled down in syringes placed in vertical position, after that liquid fraction eliminated. Syringes with fat filled up with Ringer's solution and procedure of settlement repeated 3-5 times. Washed fat placed on metallic mesh and mashed up using metallic spatula. Homogenized fat mixed with prepared ADRC and collected in syringe for further injection. Ratio fat micrograft/fat for ADRC estimated according to aspirate volume and usually forms 1:10. For example, ADRC obtained from 100 cc of fat tissue should be mixed with 10 cc of fat micrograft.

Fat micrograft preparation is also possible in Puregraft System (Cytori Therapeutics Inc) - closed disposable system for fat tissue selective washing.

Periurethral injection of fat micrograft enriched with ADRC Urethra punctured several times circle-wise at the bulbomembranous region at a depth of 5 mm under endoscopic vision and 0.5-1 mL of fat micrograft enriched with ADRC injected each time. Total volume of solution injected - approximately 8 mL. After fat micrograft injected, urethral balloon catheter placed and removed the following day.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Patient suffers from stress urinary incontinence due to insufficiency of the urethral sphincter at least for 2 years.
  • Moderate and severe grade of urinary incontinence according to assessment made by investigator.
  • Patient is familiar with Participant information sheet.
  • Patient signed informed consent form.

排除标准

  • Contraindications for local anesthesia.
  • For the patients undergone surgical treatment of prostate cancer:
  • Cancer relapse.
  • prostate-specific antigen (PSA) level >0.008 ng/mL.

结局指标

主要结局

Safety endpoints

时间窗: 4 weeks after treatment

Types, probability and severity of treatment emergent serious adverse events (SAEs) and serious adverse reactions (SARs)

次要结局

  • Efficacy endpoints(2, 4, 8, 12, 16, 24 weeks after treatment)

研究者

发起方
Burnasyan Federal Medical Biophysical Center
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Pavel Kyzlasov

MD

Burnasyan Federal Medical Biophysical Center

研究点 (2)

Loading locations...

相似试验